The US FDA has approved multiple NDAs and BLAs in July 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and […]readmore
Tags : July
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Cadila expanded its footprints in India with the launch of its two […]readmore
Shots: The two companies collaborated to develop a COVID-19 vaccine combining Medicago’s recombinant Coronavirus Virus-Like Particles (CoVLP) with GSK’s pandemic adjuvant system. The partners are planning to initiate P-I study […]readmore
Shots: Zydus’ ZyCoV-D has completed the preclinical studies and has received DCGI approval to initiate P-I/II human clinical trials in India. In its preclinical study, the vaccine demonstrated that it […]readmore
Shots: Bharat Biotech has received DCGI approval to conduct P-I & II clinical studies assessing Covaxin, developed in collaboration with ICMR and NIV. The company anticipate initiating the clinical studies […]readmore
Shots: Celltrion has completed the development of a point-of-care antigen testing kit for COVID-19 in collaboration with BBB. The POCT kit is a portable and overly sensitive device for use […]readmore
Shots: The P-III study will evaluate mRNA-1273 vs PBO in a ratio (1:1) and is expected to enroll ~30,000 patients in the US, to be conducted in collaboration with NIAID. […]readmore
Shots: Janssen has accelerated the initiation of the P-I/IIa study of its investigational Ad26.COV2-S recombinant vaccine. Earlier, the company had scheduled the clinical trial to begin in Sept’2020, the trial […]readmore
Biosimilars are key alternatives for costly Biologics therapies and saving million dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars “a reference product to biologics” which […]readmore